Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Abstract

Background/aims: The current study aims to investigate the protective effects of Bifidobacterium infantis on the abnormal immune response to inflammatory bowel disease (IBD) in dextran sodium sulfate (DSS)-induced colitis.

Methods: Eight-week-old BALB/c mice were separated into five groups at random (control, DSS, DSS+B9 [B. infantis 1×109 CFU], DSS+B8 [B. infantis 1×108 CFU], and DSS+B7 [B. infantis 1×107 CFU]). Colitis was induced by 5% DSS ad libitum for 7 days, at which time we assessed weight, the disease activity index (DAI) score, and the histological damage score. The nuclear transcription factor Foxp3 (a marker of Treg cells), cytokines interleukin-10 (IL-10) and transforming growth factor β1 (TGF-β1), and related proteins (programmed cell death ligand 1 [PD-L1] and programmed cell death 1 [PD-1]) were detected by an immunohistochemical method and Western blot.

Results: B. infantis increased weight, decreased DAI scores and histological damage scores, increased the protein expression of Foxp3 (p<0.05) and cytokines IL-10 and TGF-β1 in mouse colon tissue (p<0.05), and increased the expression of PD-L1 in the treatment groups relative to that in the DSS group (p<0.05). The effect of B. infantis on Foxp3 and PD-L1 was dose dependent in the treatment groups (p<0.05). PD-L1 was positively correlated with Foxp3, IL-10, and TGF-β1.

Conclusions: In a mouse model of IBD, B. infantis can alleviate intestinal epithelial injury and maintain intestinal immune tolerance and thus may have potential therapeutic value for the treatment of immune damage in IBD.

Keywords: Bifidobacterium infantis; Inflammatory bowel disease; Programmed cell death ligand 1; T-Lymphocytes; regulatory.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium infantisEnhanced Foxp3 ExpressionBeneficial
Moderate
Bifidobacterium infantisIncreased PD-L1 ExpressionBeneficial
Moderate
Bifidobacterium infantisMaintained Intestinal Immune ToleranceBeneficial
Large
Bifidobacterium infantisReduced Colitis SymptomsBeneficial
Moderate
Bifidobacterium infantis BI02Improved Intestinal Epithelial Intercellular IntegrityBeneficial
Large
Bifidobacterium infantis BI02Increased Body WeightBeneficial
Moderate
Bifidobacterium infantis BI02Increased Foxp3 Protein LevelsBeneficial
Moderate
Bifidobacterium infantis BI02Increased PD-L1 ExpressionBeneficial
Moderate
Bifidobacterium infantis BI02Reduced Disease Activity Index ScoresBeneficial
Moderate
Bifidobacterium infantis BI02Reduced Histological Damage ScoresBeneficial
Moderate
Bifidobacterium infantis MAK22B04IImproved Intestinal Epithelial Intercellular IntegrityBeneficial
Large
Bifidobacterium infantis MAK22B04IIncreased Foxp3 Protein ExpressionBeneficial
Moderate
Bifidobacterium infantis MAK22B04IIncreased IL-10 LevelsBeneficial
Moderate
Bifidobacterium infantis MAK22B04IIncreased PD-L1 ExpressionBeneficial
Moderate
Back to top